| Place of Origin: | China |
|---|---|
| Brand Name: | HNB |
| Certification: | ISO |
| Model Number: | Bremelanotide PT 141 |
| Minimum Order Quantity: | 1KG |
| Price: | Negotiable |
| Packaging Details: | Aluminum foil bag |
| Delivery Time: | Usually3-5days |
| Payment Terms: | L/C, D/A, D/P, T/T, Western Union, MoneyGram，Alibaba Assurance Order |
| Supply Ability: | 5000kg/Month |
| CAS: | 189691-06-3 | Mf: | C50H68N14O10 |
|---|---|---|---|
| MW: | 1025.16 | Specification: | 99% |
| Einecs No.: | N/A | Appearance: | White Crystalline Powder |
| Sample: | Available | ||
| High Light: | 189691-06-3 Sexual Enhancement Powder,Bremelanotide PT 141 Powder,189691-06-3 Bremelanotide Powder |
||
CAS: 189691-06-3 SEXUAL ENHANCEMENT POWDER BREMELANOTIDE PT 141
|
Product name |
BREMELANOTIDE PT 141 |
|
Appearance |
White Crystalline Powder |
|
CAS |
189691-06-3 |
|
MF |
C50H68N14O10 |
|
Purity |
99% |
|
Storage |
Keep in cool dry place. |
The Introductction of BREMELANOTIDE PT 141
PT141, also known as Bremelanotide, is a drug used to treat female sexual dysfunction. PT-141 has shown positive Chemicalbook results in a phase I clinical trial administered to normal premenopausal women. It helps premenopausal women with hypoactive libido to maintain a normal sexual desire.
Bremelanotide PT141 is an MC4R agonist and a synthetic peptide analogue of alpha-melanocyte stimulating hormone (α-MSH), a cyclic peptide derivative of melanocortin containing 7 amino acids, which regulates the pathways involved in the sexual response in the brain. It has been shown to have pharmacological effects and safety in the treatment of sexual dysfunction.
The Application & Function of BREMELANOTIDE PT 141
Bremelanotide PT141 has pharmacological effects and safety in the treatment of sexual dysfunction
Bremelanotide PT141 subcutaneous injection is indicated for the treatment of acquired, broadly defined HSDD in premenopausal women characterized by a low sexual desire that causes significant psychological distress or interpersonal difficulties, and is not due to a concurrent medical or psychiatric illness, relationship problems, or the use of therapeutic medications or drugs that cause euphoric, hallucinogenic, narcotic, or dependence effects. Acquired HSDD is HSDD that occurs in patients who have not previously had problems with sexual desire. broad HSDD is HSDD that occurs regardless of the type of stimulation, situation, or partner. bumetanide subcutaneous injection is not indicated for the treatment of hypogonadism in postmenopausal women or men and is not intended to enhance sexual behavior.
Other Name of BREMELANOTIDE PT 141: Bremerdam;REMELANOTIDE;Brmelanotice;BREMELANOTIDE;PT-141 USP/EP/BP;Pt-141, Bremerdam;BREMELANOTIDE PT141;Bremelanotide See B677355;Bremelanotide, PT141,PT-141;Bremelanotide,α-MSH (PT-141);N -acetyl- L -norleucyl- L -aspartyl- L -histidyl- D -phenylalanyl- L -arginyl- L -tryptophyl- L -lysine C-4.2-N-6,7-lactam
The COA of BREMELANOTIDE PT 141
